Effect of Decitabine Combined with CAG Regimen on Elderly Patients with Acute Myeloid Leukemia
Objective:To analyze the effect of Decitabine combined with CAG regimen in the treatment of elderly patients with acute myeloid leukemia(AML).Method:A total of 104 elderly AML patients treated in the Second Affiliated Hospital of Mudanjiang Medical College from July 2018 to July 2023 were selected as the study objects,and they were divided into the control group and the experimental group by random number table method,with 52 cases in each group.The control group received CAG regimen,and the experimental group received Decitabine combined with CAG Regimen.The clinical efficacy,hematopoietic ability,immune cell level and incidence of adverse reactions were compared between the two groups.Result:The total effective rate of clinical treatment in experimental group was higher than that of control group,the difference was statistically significant(P<0.05).After treatment,the hemoglobin(Hb)and platelet count(PLT)in two groups were higher than those before treatment,and the proportion of bone marrow original cells were lower than those before treatment,and Hb and PLT in experimental group were higher than those in control group,and proportion of bone marrow original cells was lower than that in control group,the differences were statistically significant(P<0.05).After treatment,the mature T lymphocytes(CD3+),helper T cells(CD4+)and cytotoxic T cells(CD8+)in both groups were lower than those before treatment,and those in experimental group were lower than those in control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Treatment with Decitabine combined with CAG regimen in elderly patients with AML has significant effects,which can effectively improve hematopoietic ability,have little impact on immune cell function,and do not increase the incidence of adverse reactions.
万方数据
维普
